ClinicalTrials.gg
Not yet recruitingNCT07707674Updated Jul 22, 2026

Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

A Phase 1 interventional study of XNW28012 in Metastatic Pancreatic Cancer, sponsored by Evopoint Biosciences Inc.. Not yet recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Evopoint Biosciences Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 298 open to participants now, 470 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Planned enrollment
987th of 1,574
24 · median 37
Started
2026
with 83 others
Phase 1
556 of 1,851
75 open now
Primary completion
2028-04
later than 317 of 469 live
Registered
1,824th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 987th largest by planned enrollment of the 1,574 interventional ones that give a count, is one of 84 that started in 2026, is one of 556 in phase 1, reaches primary completion later than 317 of the 469 other live ones, and was the 1,824th registered.

Pancreatic Neoplasms

3,904 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

298 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

293 more — sign in →

All 298 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer

03

Conditions studied

  • Metastatic Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. subjects with or cytologically confirmed PDAC, whose disease has progressed after at least 1 prior systemic therapy.
  2. Age ≥ 18 years old at the time of consent.
  3. Subjects must have a performance status of 0 or 1 on the (ECOG) Performance Scale. ECOG status of 2 can be allowed if it is a result of disease progression and warrantsdiscussion with the medical monitor.
  4. Subjects must have adequate organ function within 7 days prior to the first study drug administration, as indicated by the following laboratory values;
  5. of at least 12 weeks.
  6. Females of must have a negative pregnancy test within 7 days prior to the first dose of study drug.
  7. Non-sterile subjects must be willing to use a highly effective (e.g., IUD, pill, or condom) for the duration of the study and for 6 months after the last dose of study drug unless their partner is sterilized.
  8. Subjects are able to provide written , understand and are willing to comply with the requirements of the study.

    -

Exclusion criteria

Exclusion Criteria:

  1. A history of severe infusion reactions to other monoclonal antibodies/antibody drug conjugates (ADCs), or allergic reactions to any components of XNW28012, or treatment with TF-directed therapy.
  2. Any anti-tumor therapy within 21 days prior to the first dose, including but not limited to: small molecules, immunotherapy, chemotherapy, monoclonal antibodies, or any other experimental drugs.
  3. Any active , with the exception of the specific types of cancersunder investigation in this study and any locally recurring cancer that has been treated curatively .
  4. Have received a within 4 weeks prior to the first dose of study drug. Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed; however, intranasal influenza vaccines will not be allowed if they are attenuated live vaccines.
  5. Have received granulocyte colony stimulating factor (G-CSF) or granulocyte / macrophage colony stimulating factor support within 1 week before screening, or pegylated G-CSF within 2 weeks before screening.
  6. Subjects with toxicities (as a result of prior anti-cancer therapy) that have not improved to grade ≤ 1 or stabilized, except those AEs not considered as a likely safety risk (e.g., alopecia).
  7. Any history of pneumonitis or interstitial lung disease (ILD).
  8. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke () ≤ 3 months prior to screening is allowed if stable.
  9. Any hematological risk factors.
  10. cardiovascular/cerebrovascular conditions.
  11. Subjects have known active and/or carcinomatous meningitis.
  12. Active ocular surface disease at screening, or subjects with any prior episode of cicatricial conjunctivitis, or corneal nebula; subjects with glaucoma of CTCAE grade ≥ 2.
  13. Any history of Toxic Epidermal Necrolysis (TEN) or Steven Johnson Syndrome.
  14. Subjects who have undergone major surgery within 28 days prior to the first dose of study drug, except if the procedure is minimally invasive.
  15. Subjects with untreated chronic or chronic hepatitis B virus (HBV) carriers whose HBV DNA is higher than 500 IU/mL or subjects with positive virus (HCV) RNA. Inactive hepatitis B surface antigen (HbsAg) carriers, treated and stable hepatitis B (HBV DNA \< 500 IU/mL), and cured hepatitis C subjects may be enrolled.
  16. A known history of infection or acquired immunodeficiency syndrome (AIDS).
  17. Subjects with severe chronic or active infections requiring antibacterial, antifungal or antiviral therapy.
  18. Known immunodeficiency or any condition that requires systemic treatment with either (≥ 10 mg daily of prednisone or equivalent) or other medication within 7 days before the first dose of study drug.
  19. Subjects who have received (or plan to receive during the study treatment period) strong/moderate inhibitors or inducers, or strong/moderate CYP2D6 inhibitors within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of study drug.
  20. Have an ongoing significant, uncontrolled medical condition.
  21. Subjects who are pregnant or breastfeeding or expecting to conceive within the projected duration of the study.
  22. Underlying medical conditions or alcohol, drug abuse or dependence that, in Investigator's opinion, will be unfavorable for the administration of study drug or affect the explanation of drug toxicity or adverse events, or insufficient compliance during the study according to Investigator's judgment.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    XNW28012 2.0 mg/kg dose level

    XNW28012 2.0 mg/kg, IV, every 3 weeks (Q3W; 21-day cycles).

    Drug: XNW28012

  • Experimental
    XNW 28012 2.4 mg/kg dose level

    XNW28012 2.4 mg/kg, IV, every 3 weeks (Q3W; 21-day cycles).

    Drug: XNW28012

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Number and percentage of participants experiencing treatment-emergent adverse events (TEAEs), including assessment of severity according to CTCAE criteria.

    Time frame: From the first dose of study treatment through 30 days after the last dose of study treatment.

  2. Incidence of Serious Adverse Events (SAEs)

    Number and percentage of participants experiencing treatment-emergent serious adverse events (SAEs).

    Time frame: From the first dose of study treatment through 30 days after the last dose of study treatment.

Secondary outcomes

  1. RP2D

    To determine the optimal dose of XNW28012 for future development

    Time frame: From the first dose of study treatment through 30 days after the last dose of study treatment.

  2. Maximum Plasma Concentration (Cmax)

    Maximum observed plasma concentration of study drug following administration.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment.

  3. Area Under the Plasma Concentration-Time Curve (AUC)

    Area under the plasma concentration-time curve of study drug following administration.

    Time frame: From the first dose of study treatment through 30 days after the last dose of study treatment.

  4. Terminal Elimination Half-Life (t1/2)

    Terminal elimination half-life of study drug following administration.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment.

  5. Time to Maximum Plasma Concentration (Tmax)

    Time to reach maximum observed plasma concentration of study drug following administration.

    Time frame: From first dose of study treatment through 30 days after the last dose of study treatment.

  6. Incidence of Treatment-Emergent Anti-Drug Antibodies (ADA)

    Proportion of participants who develop treatment-emergent anti-drug antibodies during the study period.

    Time frame: From the first dose of study treatment through 30 days after the last dose of study treatment.

  7. Objective Response Rate (ORR)

    Percentage of participants with a best overall response of complete response (CR) or partial response (PR) as assessed by investigator according to \[RECIST 1.1/Lugano criteria\].

    Time frame: 24 months

  8. Duration of Response (DOR)

    Time from the first documented objective response (CR or PR) to disease progression or death, assessed according to \[criteria\].

    Time frame: 24 months

  9. Progression-Free Survival (PFS)

    Time from first dose of study treatment to documented disease progression or death from any cause.

    Time frame: 24 months

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Apr 2028, 21 months later.

Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's planned 21 months is below that.

Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 16, 2026
StartEst.
Jul 30, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07707674
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jul 30, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Jul 22, 2026

Study contacts

Yingyi Zhang
Contact
yingyi.zhang@evopointbio.com
562-796-8006

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-TF/TOP1i Antibody-drug Conjugate XNW28012

Start the discussion